CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
Rhea-AI Summary
CytomX Therapeutics (Nasdaq: CTMX) will report full year 2025 financial results on March 16, 2026, before the open of U.S. markets. The company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT the same day.
Participants can access the live webcast and archived replay on CytomX's Events and Presentations page and are advised to register at least 10 minutes before the call.
Positive
- None.
Negative
- None.
News Market Reaction – CTMX
In the Mar 4 session, CTMX gained 5.41%, reflecting a notable positive market reaction. Argus tracked a trough of -7.3% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Conference presentations | Neutral | -6.6% | Announced management presentations at two February 2026 investor conferences with webcast access. |
| Jan 08 | Business update | Neutral | -0.9% | Outlined 2026 clinical milestones for CX-2051 and CX-801, including Phase 1 expansions. |
| Nov 25 | Conference appearances | Neutral | +4.5% | Detailed December 2025 investor conference fireside chats with webcast availability for investors. |
| Nov 13 | Conference participation | Neutral | -8.8% | CEO scheduled for a fireside chat at the Jefferies London Healthcare Conference with webcast. |
| Nov 06 | Q3 2025 earnings | Neutral | -13.6% | Reported Q3 2025 financials, including $6.0M revenue and $143.6M cash with runway to Q2 2027. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including conferences and Q3 2025 earnings, often coincided with negative price reactions despite largely informational disclosures.
Over the last several months, CytomX has mainly issued conference participation updates and a Q3 2025 earnings report. The Nov 6, 2025 earnings release highlighted cash of $143.6 million and revenue of $6.0 million versus $33.4 million a year earlier, with a $21.7 million operating expense. Business updates in Jan 2026 emphasized progress for CX-2051 and CX-801. Despite these largely operational milestones, shares frequently moved negatively after news, framing today’s earnings-date announcement against a backdrop of cautious reactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report full year 2025 financial results on Monday, March 16, 2026, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT.
Participants may access the live webcast of the conference call from the Events and Presentations page of CytomX’s website at https://ir.cytomx.com/events-and-presentations. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call. An archived replay of the webcast will be available on the Company’s website.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ (formerly Stern Investor Relations)
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com
